University Clinic / Medicinal Clinic IV
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rummel, Mathias
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
ARCHED, NCT05820841: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Recruiting
3
330
Europe
R-miniCHOP + Acalabrutinib, R-miniCHOP
Universität des Saarlandes, University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital of Gießen and Marburg, Saarland University Medical Center, AstraZeneca
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
04/28
12/28
StiL NHL7-2008 MAINTAIN trial, NCT00877214: Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Checkmark P2/3 data-ASH 2012
More
Active, not recruiting
3
1272
Europe
Rituximab, Mabthera(R), Rituxan(R), Rituximab / observation
Jurgen Barth, Sponsor GmbH
Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas, Mantle-Cell Lymphomas, Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
12/24
12/24
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Recruiting
2/3
210
Europe
Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA
University of Giessen
Hairy Cell Leukemia
12/25
12/27

Download Options